GlassScriptPhysician profile
Danielle Nabers
NPI 1912562406
$6,153.65
in general payments reported to CMS, 2019-2025
28 companies · $401 in 2025
The $401 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $521 · 2022: $2,299 · 2023: $1,988 · 2024: $945 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,249 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,248.67 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,859.99 | 2021-2024 | Enbrel, Otezla, Evenity |
| Janssen Biotech, INC. | $715.06 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $620.85 | 2021-2025 | |
| Lilly USA, LLC | $606.26 | 2022-2024 | Taltz, Zepbound |
| Glaxosmithkline, LLC. | $290.53 | 2022-2023 | Benlysta |
| Aurinia Pharma U.S., INC. | $267.71 | 2021-2023 | Lupkynis |
| Ucb, INC. | $236.98 | 2022-2024 | Cimzia |
| Radius Health, INC. | $204.95 | 2022-2024 | Tymlos |
| Pfizer INC. | $203.50 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $202.99 | 2022-2024 | Saphnelo |
| Celltrion USA INC. | $142.72 | 2025 | Zymfentra, Vegzelma |
| Mylan Institutional INC. | $102.49 | 2023 | Hulio |
| Alexion Pharmaceuticals, INC. | $98.90 | 2023-2024 | Strensiq, Ultomiris, Soliris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.60 | 2023-2024 | Ofev, Cyltezo |
| Novartis Pharmaceuticals Corporation | $75.32 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $71.26 | 2022-2023 | Krystexxa |
| Genentech USA, INC. | $68.43 | 2022-2023 | Actemra |
| Sandoz INC. | $41.75 | 2023-2024 | Hyrimoz |
| Accord Healthcare, INC. | $40.05 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $38.01 | 2023 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $36.37 | 2022-2023 | Orencia |
| Fresenius Kabi USA, LLC | $29.25 | 2023 | Idacio |
| Genzyme Corporation | $25.82 | 2023 | |
| Pharmacosmos Therapeutics INC. | $24.61 | 2023 | Monoferric |
| Bioventus LLC | $21.57 | 2023 | Durolane |
| Mallinckrodt Hospital Products INC. | $20.00 | 2021 | |
| Sobi, INC | $18.92 | 2023 | |
| Organon LLC | $6.76 | 2023 | Renflexis, Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Nabers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.